INTRODUCTION
Topical corticosteroid ointments, creams, and lotions are efficacious treatments for multiple dermatoses.1 However, adherence to these treatments is often abysmal.2,3 Individualizing treatments based on patient preference may improve adherence, patient satisfaction, and clinical outcome.4,5
Other vehicle formulations may be preferred by some patients. Foams are generally easy to apply and cosmetically appealing.1,5 Although patient preference for different vehicles is variable, foams may improve some patients’ treatment satisfaction.5-7
Four topical corticosteroid foams are available – clobetasol propionate (CP) 0.05% foam, betamethasone valerate (BMV) 0.12% foam, calcipotriol 0.005% plus betamethasone dipropionate (Cal/BD) 0.064%, and desonide 0.05% foam (Table 1). The purpose of this study was to evaluate the efficacy and safety of CP, BMV, Cal/BD, and desonide foams in dermatologic diseases.
Other vehicle formulations may be preferred by some patients. Foams are generally easy to apply and cosmetically appealing.1,5 Although patient preference for different vehicles is variable, foams may improve some patients’ treatment satisfaction.5-7
Four topical corticosteroid foams are available – clobetasol propionate (CP) 0.05% foam, betamethasone valerate (BMV) 0.12% foam, calcipotriol 0.005% plus betamethasone dipropionate (Cal/BD) 0.064%, and desonide 0.05% foam (Table 1). The purpose of this study was to evaluate the efficacy and safety of CP, BMV, Cal/BD, and desonide foams in dermatologic diseases.
METHODS
A Pubmed search was conducted up to April 1, 2019 using the keywords: “clobetasol,” “betamethasone,” “dipropionate,” “valerate,” “corticosteroids,” “desonide,” “topical,” “foam,” “vehicles,” “treatment,” and “clinical trial.” Forty articles out of 314 results were selected and read related to relevance (Figure 1).
RESULTS
Clobetasol Propionate 0.05% Foam
Clobetasol propionate 0.05% foam is a super-potent topical corticosteroid indicated for treating mild-to-severe plaque-type psoriasis and other corticosteroid-responsive dermatoses in patients 12 years and older. A thin layer is applied twice daily for up to 2 weeks, with a maximum weekly dose of 50 mg.8
Efficacy
A randomized, double-blind, placebo-controlled study stratified plaque-type psoriasis subjects to either CP 0.05% foam or vehicle foam applied twice daily for 2 weeks. At week 2, more CP
Clobetasol propionate 0.05% foam is a super-potent topical corticosteroid indicated for treating mild-to-severe plaque-type psoriasis and other corticosteroid-responsive dermatoses in patients 12 years and older. A thin layer is applied twice daily for up to 2 weeks, with a maximum weekly dose of 50 mg.8
Efficacy
A randomized, double-blind, placebo-controlled study stratified plaque-type psoriasis subjects to either CP 0.05% foam or vehicle foam applied twice daily for 2 weeks. At week 2, more CP